vs
BioNexus Gene Lab Corp（BGLC）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是BioNexus Gene Lab Corp的581.4倍（$281.3M vs $483.8K）。Guardant Health, Inc.净利率更高（-45.7% vs -214.2%，领先168.5%）。Guardant Health, Inc.同比增速更快（39.4% vs -80.8%）。BioNexus Gene Lab Corp自由现金流更多（$960.1K vs $-54.2M）。过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs -54.9%）
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
BGLC vs GH — 直观对比
营收规模更大
GH
是对方的581.4倍
$483.8K
营收增速更快
GH
高出120.2%
-80.8%
净利率更高
GH
高出168.5%
-214.2%
自由现金流更多
BGLC
多$55.2M
$-54.2M
两年增速更快
GH
近两年复合增速
-54.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $483.8K | $281.3M |
| 净利润 | $-1.0M | $-128.5M |
| 毛利率 | -0.8% | 64.6% |
| 营业利润率 | -213.5% | -43.0% |
| 净利率 | -214.2% | -45.7% |
| 营收同比 | -80.8% | 39.4% |
| 净利润同比 | -197.5% | -15.8% |
| 每股收益（稀释后） | — | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGLCGH
| Q4 25 | $483.8K | $281.3M | ||
| Q3 25 | $2.5M | $265.2M | ||
| Q2 25 | $2.3M | $232.1M | ||
| Q1 25 | $2.1M | $203.5M | ||
| Q4 24 | $2.5M | $201.8M | ||
| Q3 24 | $2.6M | $191.5M | ||
| Q2 24 | $2.0M | $177.2M | ||
| Q1 24 | $2.4M | $168.5M |
净利润BGLCGH
| Q4 25 | $-1.0M | $-128.5M | ||
| Q3 25 | $-709.0K | $-92.7M | ||
| Q2 25 | $-616.2K | $-99.9M | ||
| Q1 25 | $-623.3K | $-95.2M | ||
| Q4 24 | $-348.3K | $-111.0M | ||
| Q3 24 | $-1.3M | $-107.8M | ||
| Q2 24 | $199.1K | $-102.6M | ||
| Q1 24 | $-103.8K | $-115.0M |
毛利率BGLCGH
| Q4 25 | -0.8% | 64.6% | ||
| Q3 25 | 14.8% | 64.7% | ||
| Q2 25 | 16.3% | 65.0% | ||
| Q1 25 | 16.1% | 63.3% | ||
| Q4 24 | 12.3% | 61.6% | ||
| Q3 24 | 12.4% | 61.1% | ||
| Q2 24 | 14.6% | 59.1% | ||
| Q1 24 | 15.3% | 61.2% |
营业利润率BGLCGH
| Q4 25 | -213.5% | -43.0% | ||
| Q3 25 | -27.6% | -37.3% | ||
| Q2 25 | -27.0% | -45.9% | ||
| Q1 25 | -28.9% | -54.6% | ||
| Q4 24 | -16.5% | -62.4% | ||
| Q3 24 | -50.9% | -61.3% | ||
| Q2 24 | 13.1% | -56.8% | ||
| Q1 24 | -3.3% | -59.2% |
净利率BGLCGH
| Q4 25 | -214.2% | -45.7% | ||
| Q3 25 | -27.9% | -35.0% | ||
| Q2 25 | -27.3% | -43.0% | ||
| Q1 25 | -29.2% | -46.8% | ||
| Q4 24 | -13.8% | -55.0% | ||
| Q3 24 | -51.1% | -56.3% | ||
| Q2 24 | 10.1% | -57.9% | ||
| Q1 24 | -4.4% | -68.2% |
每股收益（稀释后）BGLCGH
| Q4 25 | — | $-1.01 | ||
| Q3 25 | $-0.40 | $-0.74 | ||
| Q2 25 | $-0.34 | $-0.80 | ||
| Q1 25 | $-0.04 | $-0.77 | ||
| Q4 24 | $0.55 | $-0.90 | ||
| Q3 24 | $-0.75 | $-0.88 | ||
| Q2 24 | $0.11 | $-0.84 | ||
| Q1 24 | $-0.01 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $378.2M |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $8.6M | $-99.3M |
| 总资产 | $9.3M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BGLCGH
| Q4 25 | $2.5M | $378.2M | ||
| Q3 25 | — | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | $2.9M | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | — | $933.7M | ||
| Q1 24 | — | $1.0B |
总债务BGLCGH
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BGLCGH
| Q4 25 | $8.6M | $-99.3M | ||
| Q3 25 | $6.8M | $-354.5M | ||
| Q2 25 | $7.5M | $-305.5M | ||
| Q1 25 | $7.8M | $-250.8M | ||
| Q4 24 | $8.3M | $-139.6M | ||
| Q3 24 | $9.4M | $-60.1M | ||
| Q2 24 | $9.5M | $-1.6M | ||
| Q1 24 | $9.3M | $68.3M |
总资产BGLCGH
| Q4 25 | $9.3M | $2.0B | ||
| Q3 25 | $7.6M | $1.3B | ||
| Q2 25 | $9.4M | $1.3B | ||
| Q1 25 | $9.5M | $1.3B | ||
| Q4 24 | $10.4M | $1.5B | ||
| Q3 24 | $11.0M | $1.5B | ||
| Q2 24 | $11.1M | $1.6B | ||
| Q1 24 | $11.2M | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $961.1K | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $960.1K | $-54.2M |
| 自由现金流率自由现金流/营收 | 198.5% | -19.3% |
| 资本支出强度资本支出/营收 | 0.2% | 9.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9M | $-233.1M |
8季度趋势，按日历期对齐
经营现金流BGLCGH
| Q4 25 | $961.1K | $-26.4M | ||
| Q3 25 | $-1.2M | $-35.4M | ||
| Q2 25 | $-737.9K | $-60.3M | ||
| Q1 25 | $-824.1K | $-62.7M | ||
| Q4 24 | $219.2K | $-64.5M | ||
| Q3 24 | $-1.6M | $-51.1M | ||
| Q2 24 | $-672.3K | $-94.0M | ||
| Q1 24 | $-37.2K | $-30.3M |
自由现金流BGLCGH
| Q4 25 | $960.1K | $-54.2M | ||
| Q3 25 | $-1.2M | $-45.8M | ||
| Q2 25 | $-759.4K | $-65.9M | ||
| Q1 25 | $-833.1K | $-67.1M | ||
| Q4 24 | $215.2K | $-83.4M | ||
| Q3 24 | $-1.8M | $-55.3M | ||
| Q2 24 | $-674.1K | $-99.1M | ||
| Q1 24 | $-59.1K | $-37.2M |
自由现金流率BGLCGH
| Q4 25 | 198.5% | -19.3% | ||
| Q3 25 | -48.9% | -17.3% | ||
| Q2 25 | -33.6% | -28.4% | ||
| Q1 25 | -39.0% | -33.0% | ||
| Q4 24 | 8.5% | -41.3% | ||
| Q3 24 | -68.5% | -28.9% | ||
| Q2 24 | -34.1% | -55.9% | ||
| Q1 24 | -2.5% | -22.1% |
资本支出强度BGLCGH
| Q4 25 | 0.2% | 9.9% | ||
| Q3 25 | 0.2% | 3.9% | ||
| Q2 25 | 0.9% | 2.4% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 0.2% | 9.4% | ||
| Q3 24 | 7.6% | 2.2% | ||
| Q2 24 | 0.1% | 2.9% | ||
| Q1 24 | 0.9% | 4.1% |
现金转化率BGLCGH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.38× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGLC
暂无分部数据
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
